SCHEMBL21821964

SCHEMBL21821964

CN(C)C=C1C(=O)CC(c2ccncc2)CC1=O

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 10/20 0.71
CYP19A1 P11511 1/20 0.49
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTT P42858 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 2/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HIF1A Q16665 1/20 0.36
NPC1 O15118 1/20 0.34
HSP90AA1 P07900 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
LMNA P02545 2/20 0.33
BUB1 O43683 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1780317 0.83 MAP1LC3B (1.00) MAP1LC3BMEN1KMT2AHTTMAPT
SCHEMBL1779869 0.82 MAP1LC3B (1.00) MAP1LC3BMEN1KMT2AHTTL3MBTL1
SCHEMBL21822056 0.82 MAP1LC3B (0.68) MAP1LC3BCYP19A1MEN1KMT2AHTT
SCHEMBL21774003 0.81 MAP1LC3B (0.70) MAP1LC3BMEN1KMT2AL3MBTL1MAPT
SCHEMBL1780581 0.81 MAP1LC3B (1.00) MAP1LC3BMEN1KMT2AHTTL3MBTL1
SCHEMBL1781754 0.81 MAP1LC3B (1.00) MAP1LC3BMEN1KMT2AHTTL3MBTL1
SCHEMBL21821985 0.81 MAP1LC3B (0.74) MAP1LC3BMEN1KMT2AHTTL3MBTL1
SCHEMBL21821722 0.80 MAP1LC3B (0.71) MAP1LC3BMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL21821945 0.77 MAP1LC3B (0.63) MAP1LC3BKMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL21821935 0.75 MAP1LC3B (0.68) MAP1LC3BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 EP disclosed
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 EP disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 US disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 US disclosed
EP-3632903-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2020-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof ATG7, SQSTM1, BECN1 MAP1LC3B 15/4885CYP19A1 2800/4885MEN1 3447/4885
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF ATG7, SQSTM1, BECN1 MAP1LC3B 15/4885CYP19A1 2800/4885MEN1 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.